Is It Too Late to Consider CorMedix After DefenCath Progress and Strong Price Gains? [Yahoo! Finance]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Yahoo! Finance
The stock has quietly put up some strong numbers, with shares up 1.5% over the last week, 18.3% over the last month, 45.0% year to date, and 201.0% over three years. Recent news around CorMedix has largely focused on progress with its lead asset DefenCath, including regulatory milestones and commercialization preparations that have shifted sentiment toward the company. Investors have also been watching partnership updates and market launch timelines, which help explain why the stock has re rated so sharply. Despite that surge, CorMedix still scores a solid 5/6 on our valuation checks , suggesting the market may not be fully reflecting its fundamentals yet. In the sections ahead we will walk through those valuation methods before digging into an even more powerful way to think about what the stock is really worth. CorMedix delivered 34.4% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry. A Discounted Cash Flow model estimates what
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix (NASDAQ:CRMD) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.MarketBeat
- CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCathGlobeNewswire
- 5 High Earnings Yield Value Picks Ahead of Key Economic Reports [Yahoo! Finance]Yahoo! Finance
- Assessing CorMedix (CRMD): Is the Current Share Price Reflecting Its True Value? [Yahoo! Finance]Yahoo! Finance
- Cormedix Inc (CRMD) Q3 2025 Earnings Call Highlights: Record Financial Performance and ... [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 11/12/25 - Beat
CRMD
Sec Filings
- 12/18/25 - Form 144
- 12/11/25 - Form 4
- 12/10/25 - Form 4
- CRMD's page on the SEC website